Trial reportHaematologica2016
Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab.
Trial report in Haematologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.The Cochrane database of systematic reviews · 2021Pooled it
- Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study.Leukemia · 2019Trial
- The Prognostic Impact of Dose-attenuated R-CHOP Therapy for Elderly Patients with Diffuse Large B-cell Lymphoma.Internal medicine (Tokyo, Japan) · 2018Trial
- Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.Therapeutic advances in hematology · 2022Review
- Novel model predicts prognosis for patients with diffuse large B-cell lymphoma in first relapse after initial R-CHOP therapy: a single-institution study in China.The Journal of international medical research · 2021Article
- Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients.The oncologist · 2021Review
- Phase I, multicenter, dose-escalation study of avadomide in adult Japanese patients with advanced malignancies.Cancer science · 2021Article
- New agents and regimens for diffuse large B cell lymphoma.Journal of hematology & oncology · 2020Review
- Current Immunotherapy Approaches in Non-Hodgkin Lymphomas.Vaccines · 2020Review
- Complete metabolic remission in an 84-year old patient with relapsed/refractory diffuse large B-cell lymphoma following combination immunotherapy with lenalidomide plus rituximab.International journal of hematology · 2020Article
- Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States.JCO global oncology · 2020Review
- Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT).Bone marrow transplantation · 2020Article
- Hematopoietic-cell transplantation for lymphoma in the era of genetically engineered cellular therapy: it's not quite time to scrap the old vehicle for the new car.Current opinion in hematology · 2019Review
- The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma.Investigational new drugs · 2019Article
- Application of Lenalidomide on Diffused Large B-cell Lymphoma: Salvage, Maintenance, and Induction Treatment.Chinese medical journal · 2018Article
- How I manage patients with relapsed/refractory diffuse large B cell lymphoma.British journal of haematology · 2018Review
- Current Progress in EBV-Associated B-Cell Lymphomas.Advances in experimental medicine and biology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.